Current International Projects
Azobenzene derivatives as potential therapeutics for Alzheimer's disease
• Duration: 1. 1. 2023 – 31. 12. 2024
• Program: Mobility Programme (MAD)
• Principal Investigator: RNDr. Bednáriková Zuzana, PhD.
Non-globular proteins in the era of Machine Learning
• Duration: 25. 10. 2022 – 24.10.2026
• Program: COST: European Cooperation in Science & Technology
• Principal Investigator for Slovakia: RNDr. Bednáriková Zuzana, PhD.
Discovery and Mechanism of Small Molecules from Traditional Chinese Herbs for Multitarget directed Therapy of Neurodegenerative Diseases
• Duration: 1. 7. 2024 – 30. 6. 2026
• Program: APVV-bilateral
• Principal Investigator for Slovakia: doc. RNDr. Gažová Zuzana, DrSc.
Inhibition of Aβ Peptides Aggregation by Late Embryogenesis Abundant Proteins: A New Approach for Alzheimer’s Disease Treatment
• Duration: 1. 1. 2024 – 31. 12. 2025
• Program: APVV-bilateral
• Principal Investigator for Slovakia: RNDr. Bednáriková Zuzana, PhD.
Current National Projects
Multicomponent ligands as modulators of targets associated with the pathogenesis of Alzheimer's disease
• Duration: 1. 7. 2023 – 30. 6. 2027
• Program: APVV
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
Ionic liquids and deep eutectic solvents as modulators of protein stability and aggregation
• Duration: 1. 1. 2022 – 31. 12. 2025
• Program: VEGA
• Principal Investigator: RNDr. Fedunová Diana, PhD.
Unraveling the early events of protein amyloid aggregation: from mechanism to therapy
• Duration: 1. 1. 2021 – 31. 12. 2024
• Program: VEGA
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
Low-molecular-weight compounds targeting amyloid-related diseases
• Duration: 1. 7. 2024 – 31. 12. 2025
• Program: PostdokGrant (SAS)
• Principal Investigator: RNDr. Miroslav Gančár, PhD.
Past projects
Stability and aggregation of globular proteins in the presence of biocompatible ionic liquids
• Duration: 1. 1. 2021 – 31. 12. 2022
• Program: Mobility Programme (MAD)
• Principal Investigator: RNDr. Fedunová Diana, PhD.
MULTIHIT – Multi-target inhibitors of poly/peptides associated with Alzheimer's disease
• Duration: 1. 7. 2019 – 1. 6. 2023
• Pogram: APVV
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
DIAGNAD – Research and development of compounds for Alzheimer's disease diagnostics
• Duration: 1. 1. 2021 – 31. 12. 2022
• Program: EU Structural Funds for Research and Innovation
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
NANOVIR – Nanoparticles for solving diagnostic and therapeutic problems with Covid-19
• Duration: 1. 1. 2021 – 30. 6. 2023
• Program: EU Structural Funds for Research and Innovation
• Principal Investigator: Ing. Zavišová Vlasta, PhD.
BIOVID-19 – Development of biomodels to improve the evaluation of the efficiency of drugs and compounds with the potential to treat Covid-19
• Duration: 1. 1. 2021 – 30. 6. 2023
• Program: EU Structural Fonds for Research and Innovation
• Principal Investigator: Ing. Koneracká Martina, CSc.
Non-globular proteins – from sequence to structure, function and application in molecular pathophysiology
• Duration: 1. 8. 2015 – 31. 5. 2019
• Program: COST: European Cooperation in Science & Technology
• Principal Investigator for Slovakia: doc. RNDr. Gažová Zuzana, DrSc.
Interactions of nanoparticles with amyloid fibrils: from therapy to nanomaterials
• Duration: 1. 1. 2022 – 31. 12. 2023
• Program: APVV-bilateral
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
Stability and aggregation of globular proteins in the presence of biocompatible ionic liquids
• Duration: 1. 1. 2021 – 31. 12. 2022
• Program: Mobility Programme (MAD)
• Principal Investigator: RNDr. Diana Fedunová, PhD.
Study of amyloid protein aggregation in vitro and in cerebrospinal fluid
• Duration: 1. 1. 2015 – 31. 12. 2020
• Program: Inter-institutional agreement between the Institute of Experimental Physics, SAS and the National Institute of Mental Health (Czech Republic)
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
Identification and mechanism of action of small molecules used in traditional Chinese medicine for the treatment of Alzheimer's disease
• Duration: 1. 1. 2018 – 31. 12. 2019
• Program: APVV-bilateral
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
Effect of small molecules and nanoparticles on amyloid aggregation of poly/peptides
• Duration: 1. 1. 2016 – 31. 12. 2018
• Program: SAS-MOST JRP
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
Utilization of multitarget low molecular weight compounds from traditional Chinese herbs in the treatment of Alzheimer's disease
• Duration: 1. 1. 2016 – 31. 12. 2017
• Program: APVV-bilateral
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
Protein amyloid aggregation on hybrid surfaces
• Duration: 1. 1. 2013 – 31. 12. 2017
• Program: Inter-academic agreement on scientific cooperation between CNR (Italy) and SAS (Slovakia)
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
Supramolecular protein complexes – conformational transitions, stability, and aggregation
• Duration: 1. 1. 2018 – 31. 12. 2021
• Program: VEGA
• Principal Investigator: RNDr. Diana Fedunová, PhD.
Self-assembly of poly/peptides into amyloid aggregates – mechanism, inhibition and cytotoxicity
• Duration: 1. 1. 2018 – 31. 12. 2020
• Program: VEGA
• Principal Investigator: doc. RNDr. Gažová Zuzana, DrSc.
New methods in statistical and correlation analysis of parametric surface models and their distributions
• Duration: 1. 1. 2019 – 31. 12. 2021
• Program: VEGA
• Principal Investigator: RNDr. Jozef Marek, PhD.
Study of the stability and aggregation of natively unfolded proteins
• Duration: 1. 1. 2019 – 31. 12. 2021
• Program: VEGA
• Principal Investigator: RNDr. Diana Fedunová, PhD.
Study of the effect of hybrid molecules on amyloid aggregation of globular and intrinsically disordered proteins
• Duration: 1. 1. 2022 – 31. 12. 2022
• Program: DoktoGrant (SAS)
• Principal Investigator: RNDr. Barbora Borovská
Ionic liquids as modulators of amyloid aggregation
• Duration: 1. 1. 2020 – 31. 12. 2020
• Program: DoktoGrant (SAS)
• Principal Investigator: RNDr. Vladimír Vaník, PhD.